Skip to main content

Table 5 Primary reason for early discontinuation among all randomized study participants by study

From: Summary of anti-malarial prophylactic efficacy of tafenoquine from three placebo-controlled studies of residents of malaria-endemic countries

Study Treatment Total early withdrawal Adverse experience Insufficient therapeutic effecta Protocol deviation Lost to follow-up Movedb Other or unknown
030 Placebo 100 0 93 (93.0 %) 2 (2.0 %) 3 (3.0 %) NR 2 (2.0 %)
TQ 200-mg weekly 97 2 (2.1 %) 88 (90.7 %) 1 (1.0 %) 3 (3.1 %) NR 3 (3.1 %)
MQ 250-mg weekly 97 1 (1.0 %) 89 (91.8 %) 3 (3.1 %) 1 (1.0 %) NR 3 (3.1 %)
Total 294 3 (1.0 %) 270 (91.8 %) 6 (2.0 %) 7 (2.4 %) NR 8 (2.7 %)
043 Placebo 27 0 22 (81.5 %) 1 (3.7 %) 4 (14.8 %) NR 0
TQ 400-mg load only 18 1 (5.6 %) 5 (27.8 %) 2 (11.1 %) 9 (50.0 %) NR 1 (5.6 %)
TQ 200-mg weekly 13 1 (7.7 %) 1 (7.7 %) 8 (61.5 %) 3 (23.1 %) NR 0
TQ 400-mg weekly 10 0 0 6 (60.0 %) 4 (40.0 %) NR 0
Total 68 2 (2.9 %) 28 (41.2 %) 17 (25.0 %) 20 (29.4 %) NR 1 (1.5 %)
045 Placebo 72 NR 62 (86.1 %) NR NR NR 10 (13.9 %)
TQ 25-mg weekly 35 NR 26 (74.3 %) NR NR NR 9 (25.7 %)
TQ 50-mg weekly 16 NR 2 (12.5 %) NR NR NR 14 (87.5 %)
TQ 100-mg weekly 8 NR 0 NR NR NR 8 (100.0 %)
TQ 200-mg weekly 18 NR 1 (5.6 %) NR NR NR 17 (94.4 %)
MQ 250-mg weekly 4 NR 0 NR NR NR 4 (100.0 %)
Total 153 NR 91 (59.5 %) NR NR NR 62 (40.5 %)
  1. The percentage for each reason is based on the total number of subjects withdrawing early in each treatment group
  2. TQ tafenoquine, MQ mefloquine, NR information not reported in the original studies
  3. aInsufficient therapeutic effect or confirmed parasitemia
  4. bMoved outside of endemic area with no reported malaria infection